The global market for breast cancer diagnostics is anticipated to reach a market value of $4.0 billion in 2022 and is expected to grow at a CAGR of 7% from 2022 to 2032 to reach a market value of $7.9 billion. The prevalence of breast cancer is rising, it is reoccurring, and there are more tests available, all of which are having a favorable effect on the need for breast cancer detection. Additionally, as the tendency towards early diagnosis of breast cancer develops, there is an increase in demand for breast cancer diagnoses.
Offers in this part entail many open doors, including item creation, appropriation, retail, and exhibition management. Fact.MR’s examiners have appeared in various assessments and forecasts of the demand for breast cancer diagnostics market at the global and provincial level, utilizing extensive essential and extensive selective exploration.
Download a sample copy of this report:–https://www.factmr.com/connectus/sample?flag=S&rep_id=55?PJ
Market Players: –
- Bio-Rad Labs Inc.
- Illumina Co., Ltd.
- Biocept Co., Ltd.
- Epigenomics AG
- AstraZeneca PLC
- Myriad Genetics Inc.
- Quest diagnostic integration.
competitive landscape
Major providers of breast cancer diagnosis are committed to providing diagnostic solutions that provide early detection of breast cancer. Key market players are also investing in research and development of fast, accurate and cost-effective diagnostic solutions.
- In September 2021, Vice President of India Shri M. Venkaiah Naidu launched the first breast cancer helpline established by Ushalakshmi Breast Cancer Foundation. This is a new step for the country to spread breast cancer awareness.
- Actress and model Elizabeth Hurley opened a cancer support center in London in September 2021 ahead of Cancer Awareness Month. The support center was named Future Dreams House.
- In October 2021, to raise awareness of breast cancer, WellSpan Health and Capital Blue Cross have teamed up to launch a mobile mammography motor coach with the goal of increasing breast cancer screening in five countries.
Major Segments Covered in Breast Cancer Diagnosis Report
- By test type
- CA test for breast cancer
- BRCA test for breast cancer
- ER & PR tests for breast cancer
- CEA test for breast cancer
- KRAS mutation screening for breast cancer
- HER 2 test for breast cancer
- PSA test for breast cancer
- EGFR mutation screening for breast cancer
- Immunohistochemistry for breast cancer
- etc
- By end user
- Hospital related laboratory
- independent diagnostic lab
- cancer research institute
- etc
Technological Advancements
The breast cancer diagnostics landscape has seen a wave of technological advancements that promise to revolutionize the way we detect and manage the disease. One of the most exciting developments is the use of artificial intelligence (AI) and machine learning algorithms to interpret mammograms and other medical images. Companies like Google Health and IBM Watson are actively working on AI tools that can assist radiologists in identifying subtle patterns and irregularities in breast tissue, potentially improving diagnostic accuracy.
Furthermore, liquid biopsy techniques have gained attention for their non-invasive and highly sensitive approach to detecting cancer. These tests involve analyzing small amounts of blood for the presence of tumor-specific markers or fragments of DNA shed by cancer cells. Not only can liquid biopsies aid in early detection, but they can also monitor treatment responses and track the development of resistance to therapy.
Regional analysis includes:
- North America (USA, Canada)
- Latin America (Brazil, Mexico, Argentina, Chile, Peru, rest of LATAM)
- EU – (Germany, France, Italy, Spain), UK, Benelux (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Republic, etc.), Rest of Europe
- CIS and Russia
- Japan
- Asia Pacific excluding Japan (Greater China, India, Korea, ASEAN countries, rest of APEJ)
Current State of the Breast Cancer Diagnostics Market
The breast cancer diagnostics market has witnessed significant growth and transformation in recent years. It encompasses a wide range of diagnostic tools and techniques, including mammography, breast ultrasound, MRI, biopsy, and molecular diagnostics. Mammography remains the gold standard for breast cancer screening, offering cost-effective and widely available detection. However, there is a growing shift towards more advanced techniques that provide greater accuracy and early detection.
One notable development is the increasing adoption of digital mammography and 3D tomosynthesis, which offer improved imaging quality and reduce false-positive results. These technologies have become more accessible, leading to better detection rates and reduced patient anxiety. Additionally, the integration of artificial intelligence (AI) in mammography interpretation has shown promising results in improving diagnostic accuracy.
Customize this report for your specific research solution: https://www.factmr.com/connectus/sample?flag=RC&rep_id=55?PJ
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: [email protected]